Online inquiry

IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5188MR)

This product GTTS-WQ5188MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5188MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13827MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ12279MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ7229MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ5666MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ11935MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ13274MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ15363MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ871MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-176
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW